Literature DB >> 166949

Antibody patterns to herpesviruses in kaposi's sarcoma: serological association of european kaposi's sarcoma with cytomegalovirus.

G Giraldo, E Beth, F M Kourilsky, W Henle, G Henle, V Miké, J M Huraux, H K Andersen, M R Gharbi, S K Kyalwazi, A Puissant.   

Abstract

Sera from patients with Kaposi's sarcoma (KS) were examined for antibody titres to cytomegalovirus (CMV), Epstein-Barr virus (EBV) and herpes simplex virus (HSV) types 1 and 2 by four techniques: indirect haemagglutination (IHA), complement fixation (CF), virus neutralization (NT) and indirect immunofluorescence (IF). The patients were classified, according to the stage of disease, as progressive and regressive. Control sera were obtained from healthy adults, matched for age, sex, race, socioeconomic status and geographic location, as well as from patients with melanoma, some of whom were receiving chemotherapy similar to that given to the KS patients. All KS sera contained CMV-neutralizing antibodies. Seventy-five percent of the European KS patients, mainly regressors, showed elevated anti-CMV titres by IHA with a significant increase in the geometric mean over the corresponding healthy adult group and the melanoma group. An overrepresentation of high anti-CMV titres, although less marked, was found by CF. There was no significant association with antibodies to EBV, HSV-1 and HSV-2 related antigens. By contrast, the African KS patients, mainly progressors, did not show a serologic association with CMV or with EBV and HSV-1 and 2. The implication of these results is discussed.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 166949     DOI: 10.1002/ijc.2910150516

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

1.  Kaposi's sarcoma in two primary liver allograft recipients occurring under FK506 immunosuppression.

Authors:  Zaklyah Kadry; Oscar Bronsther; David H Van Thiel; Parmjeet Randhawa; John J Fung; Thomas E Starzl
Journal:  Clin Transplant       Date:  1993-01-01       Impact factor: 2.863

2.  In situ hybridization analysis of cytomegalovirus lytic infection in Kaposi's sarcoma associated with AIDS. A study of 14 autopsy cases.

Authors:  H Hashimoto; H Müller; F Müller; H L Schmidts; H J Stutte
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

3.  Multifactorial etiology of Kaposi' sarcoma: a hypothesis.

Authors:  Harry W Haverkos
Journal:  J Biosci       Date:  2008-12       Impact factor: 1.826

Review 4.  The status of CMV as a human pathogen.

Authors:  P D Griffiths; J E Grundy
Journal:  Epidemiol Infect       Date:  1988-02       Impact factor: 2.451

Review 5.  Epidemiology and pathogenesis of Kaposi's sarcoma-associated herpesvirus.

Authors:  C Boshoff; R A Weiss
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

6.  Failure to demonstrate early and late antigens of cytomegalovirus in tissue cultures from Kaposi's sarcoma patients.

Authors:  D Cerimele; S Scappaticci; E Cattaneo; F Cottoni
Journal:  Arch Dermatol Res       Date:  1983       Impact factor: 3.017

7.  Antibodies to cytomegalovirus in homosexual and heterosexual men attending an STD clinic.

Authors:  A Mindel; S Sutherland
Journal:  Br J Vener Dis       Date:  1984-06

8.  Vesicular stomatitis virus pseudotypes produced by cells abortively infected or transformed by human cytomegalovirus.

Authors:  E Gönczöl; I Boldogh; L Váczi
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

9.  Expression of the human cytomegalovirus genome in mouse cells and in human-mouse heterokaryons.

Authors:  I Boldogh; E Gönczöl; L Gärtner; G Váczi
Journal:  Arch Virol       Date:  1977       Impact factor: 2.574

10.  CD40 antigen is expressed by endothelial cells and tumor cells in Kaposi's sarcoma.

Authors:  J Pammer; A Plettenberg; W Weninger; B Diller; M Mildner; A Uthman; W Issing; M Stürzl; E Tschachler
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.